drugset / Trial / NCT05470868
Safety and Tolerability of PRO-185
NaSingle-groupOpen-labelTreatment
Summary
Phase I Study to evaluate safety and tolerability of PRO-185 (naphazoline/hypromellose) ophthalmic solution through evaluation of vital signs, ocular signs such as intraocular pressure, hyperemia and mydriasis and adverse events.
Timeline
- Start
- 2023-02-04
- Primary completion
- 2023-05-22
- Completion
- 2023-05-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hypromellose | Unknown | 0.2 % | Other |
| Subject | Naphazoline | Small molecule | 0.03 % | Other |